These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8246700)

  • 1. Healthy-years equivalents versus quality-adjusted life years: in pursuit of progress.
    Mehrez A; Gafni A
    Med Decis Making; 1993; 13(4):287-92. PubMed ID: 8246700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are healthy-years equivalents an improvement over quality-adjusted life years?
    Johannesson M; Pliskin JS; Weinstein MC
    Med Decis Making; 1993; 13(4):281-6. PubMed ID: 8246699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ranking properties of healthy-years equivalents and quality-adjusted life-years under certainty and uncertainty.
    Johannesson M
    Int J Technol Assess Health Care; 1995; 11(1):40-8. PubMed ID: 7706013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QALYs, HYEs and individual preferences--a graphical illustration.
    Johannesson M
    Soc Sci Med; 1994 Dec; 39(12):1623-32. PubMed ID: 7846559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economics, health and health economics: HYEs (healthy-years equivalent) versus QALYs (quality-adjusted live-year).
    Gafni A; Birch S; Mehrez A
    J Health Econ; 1993 Oct; 12(3):325-39. PubMed ID: 10129840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QALYs (quality-adjusted life-years) versus HYEs (healthy years equivalents).
    Culyer AJ; Wagstaff A
    J Health Econ; 1993 Oct; 12(3):311-23. PubMed ID: 10129839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QALYs and HYEs (healthy year equivalents): under what conditions are they equivalent?
    Bleichrodt H
    J Health Econ; 1995 May; 14(1):17-37. PubMed ID: 10143487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QALYs versus HYEs--what's right and what's wrong. A review of the controversy.
    Ried W
    J Health Econ; 1998 Oct; 17(5):607-25. PubMed ID: 10185514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporating feelings related to the uncertainty about future health in utility measurement.
    Gandjour A
    Health Econ; 2008 Oct; 17(10):1207-13. PubMed ID: 18074407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs).
    Mehrez A; Gafni A
    Pharmacoeconomics; 1992 May; 1(5):338-45. PubMed ID: 10146998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality-adjusted life years, utility theory, and healthy-years equivalents.
    Mehrez A; Gafni A
    Med Decis Making; 1989; 9(2):142-9. PubMed ID: 2501627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The healthy-years equivalents: how to measure them using the standard gamble approach.
    Mehrez A; Gafni A
    Med Decis Making; 1991; 11(2):140-6. PubMed ID: 1865782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthy years equivalents versus time trade-off. Ambiguity on certainty and uncertainty.
    Rittenhouse BE
    Int J Technol Assess Health Care; 1997; 13(1):35-48. PubMed ID: 9119622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthy-year equivalents in major joint replacement. Can patients provide meaningful responses?
    Llewellyn-Thomas HA; Arshinoff R; Bell M; Williams JI; Naylor CD
    Int J Technol Assess Health Care; 2002; 18(3):467-84. PubMed ID: 12391941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QALYs, HYEs, and the loss of innocence.
    Fryback DG
    Med Decis Making; 1993; 13(4):271-2. PubMed ID: 8246697
    [No Abstract]   [Full Text] [Related]  

  • 17. Measuring utilities of severe facial disfigurement and composite tissue allotransplantation of the face in patients with severe face and neck burns from the perspectives of the general public, medical experts and patients.
    Chuback J; Yarascavitch B; Yarascavitch A; Kaur MN; Martin S; Thoma A
    Burns; 2015 Nov; 41(7):1524-31. PubMed ID: 26068209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating risk attitude into Markov-process decision models: importance for individual decision making.
    Cher DJ; Miyamoto J; Lenert LA
    Med Decis Making; 1997; 17(3):340-50. PubMed ID: 9219195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [QALYS or not QALYS: that is the question?].
    Moatti JP; Auquier P; Le Coroller AG; Macquart-Moulin G
    Rev Epidemiol Sante Publique; 1995 Dec; 43(6):573-83. PubMed ID: 8552855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appraising the use of contingent valuation: a note in response.
    Fox-Rushby J
    Health Econ; 1993 Dec; 2(4):361-2; discussion 363-5. PubMed ID: 8142998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.